Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-methyl-d-tryptophan + adenovirus-p53 transduced dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Lumos Pharma
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Oral, Intradermal
01
Overview
This is a combination therapy consisting of **indoximod (1-methyl-d-tryptophan)**, an oral small molecule inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that modulates immune suppression in tumors[2][6][8], and **adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine**, a cancer immunotherapy where autologous dendritic cells are genetically modified with an adenoviral vector encoding the wild-type p53 tumor suppressor gene to stimulate anti-cancer immune responses[1][4][10]. The combination aims to enhance immunologic responses against tumors by both activating cytotoxic T lymphocytes targeting p53-expressing cancer cells and blocking immunosuppressive IDO activity. The therapy has been evaluated in clinical trials for metastatic solid tumors and invasive breast cancer[6][8].
- Other names
- indoximod + adenovirus-p53 transduced dendritic cell vaccine1-methyl-d-tryptophan + Ad.p53-DC vaccine
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on 1-methyl-d-tryptophan + adenovirus-p53 transduced dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-methyl-d-tryptophan + adenovirus-p53 transduced dendritic cell vaccine.